These findings are similar to a New York case series that found no increased risk of hospitalization due to COVID-19 in individuals with the immune-mediated inflammatory disease on IL-17 inhibitors compared to the general population (OR 0.97; 95% CI, 0.72–1.31) [24•]. The gene discussed is IL17A; the disease is COVID-19.